Thin Film Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 9.30 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Thin Film Drugs Market Analysis
The thin film drug market studied was projected to grow with a CAGR of nearly 9.3% over the forecast period.
COVID-19 had a significant impact on the growth of the market during the pandemic period. The demand for thin film products was notably affected due to the launch of innovative and advanced technologies for the treatment of COVID-19 disease. For instance, in May 2022, Thin Film Freezing Pharmaceuticals delivered a platform presentation with data on stabilizing and delivering antivirals, antibodies, and vaccines using thin film freezing technology in the fight against COVID-19 and other viral infections. Thus, the pandemic outbreak led to the introduction of advanced technologies, thereby significantly impacting the market growth during the pandemic period. In addition, the demand for thin film drugs is expected to remain intact owing to the rising focus on treating various chronic disorders, thereby contributing to the market's growth over the forecast period.
The increasing prevalence of diseases such as migraine, schizophrenia, opioid dependence, and others, along with rising demand for effective thin film drugsOpioid, are expected to contribute to the market's growth. For instance, the article published by DN article in January 2022 states that 1 in 7 people worldwide suffers from migraine annually, and 14.7% of people worldwide had migraine in 2021. The same source also mentioned that around 2% of the world's population suffers from chronic migraines annually. Similarly, according to the NCBI article published in June 2022, Opioid use disorders affect over 16 million people worldwide annually. Such increasing prevalence of migraine and Opioids prevalence is expected to drive the demand for thin film drugs, thereby contributing to the market's growth.
Furthermore, the growing investments in research and development of thin film drugs are expected to boost the market growth. For instance, in November 2022, Jurata Thin Film raised initial investment funds totaling USD 4.87 million to develop the thin film drug technology. The funds raised in this investment supported the design and built a pilot-scale manufacturing line capable of fabricating over 1,000 doses of biologic-loaded thin films per hour.
However, the availability of substitute drugs is expected to hinder pharmaceutical companies' market growth over the forecast period.
Thin Film Drugs Market Trends
This section covers the major market trends shaping the Thin Film Drugs Market according to our research experts:
Schizophrenia is Expected to Hold a Significant Share in the Market Over the Forecast Period
Schizophrenia is characterized by delusions, hallucinations, and other cognitive difficulties, often lifelong struggles. It is a chronic and severe mental disorder affecting a person's thoughts, feelings, and behavior. The major factors boosting the segment are the increasing prevalence of Schizophrenia Schizophrenia, the increasing geriatric population, and the rising demand for effective delivery method of drugs.
For instance, according to the WHO data, in 2022, schworldwideSchizophreniafects 24 million peopleSchizophreniaworldwide annually. Also, the European Journal of Public Health, in November 2021, mentioned that among the European Union population, the estimated incidence of schizophrenia was 15.2 per 100,000 persons annually. Such prevalence of Schizophrenia is expected to contribute to the demand for thin film drugs, ultimately boosting segment growth. Furthermore, the rising geriatric population is also expected to contribute to the growth of the studied segment. Additionally, the report published by the UN in 2022 mentioned that the share of the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. Such a rising geriatric population prone to develop schizophrenia disorders is expected to drive the growth of the studied segment over the forecast period.
Also, the increasing product approvals are expected to drive the growth of the studied segment. For instance, in April 2022, BioXcel Therapeutics received US FDA approval for the IGALM, a sublingual film for the acute treatment of agitation associated with Schizophrenia or bipolar I or II disorder in adults. This can be self-administrated by patients under the supervision of a healthcare provider.
Thus the factors mentioned above, such rising prevalence of Schizophrenia, the rising geriatric population, and increasing product approvals, are expected to drive the growth of the studied segment during the forecast period.
North America is Expected to Hold Notable Share in the Market Over the Forecast Period
North America is expected to dominate the overall thin film drug market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, advanced technologies used in pharmaceutical research, and development for the discovery of novel drug delivery techniques.
The increasing prevalence of target diseases, such as schizophrenia, migraine, opioid disorders, and others is expected to drive the demand for thin film drugs, thereby contributing to the growth of the market. For instance, the NCBI article published in June 2022, mentioned that opioid use disorders affected over 2.1 million in the United States annually. Also, American Migraine Foundation data published in February 2022, mentioned that approximately 30 million Americans are affected by migraine in 2022. Likewise, the NCBI article published in September 2021, the prevalence of migraine in Canada was to be in the range of approximately 8.3% to 10.2%, annually. Such increasing prevalence of target diseases leading to the growing demand for thin film drugs is expected to contribute to the growth of the market.
Moreover, the increasing market player activities such as strategic agreements, collaborations, partnerships, and others for the development of thin film drugs, are expected to drive the growth of the market. For instance, in March 2022, TFF Pharmaceuticals and Catalent collaborated on the generation, testing, and manufacturing of dry powder formulation using thin film freezing technology. Also, in May 2021, LTS Lohman Therapie-Systeme AG announced a feasibility agreement with Revive Therapeutics to develop and manufacture a proprietary oral psilocybin thin film strip for the treatment of mental illness.
Thus, the rising prevalence of target disorders, increasing demand for thin film drugs, and presence of market players are expected to contribute to the growth of the market in this region.
Thin Film Drugs Industry Overview
The thin film drugs market is moderately competitive and consists of several major players. Some companies currently dominating the market are ZIM Laboratories Limited, Aquestive Therapeutics, Indivior PLC, Tesa SE (Tesa Labtec GmbH), Pfizer, Inc., ARx, LLC., Solvay, IntelGenx. and others.
Thin Film Drugs Market Leaders
-
ZIM Laboratories Limited
-
Aquestive Therapeutics
-
Indivior PLC
-
Tesa Labtec GmbH
-
Pfizer, Inc.
*Disclaimer: Major Players sorted in no particular order
Thin Film Drugs Market News
- In November 2022, Aptar Pharma collaborated with TFF pharmaceutical; a company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform. The collaboration aimed at developing and testing the administration of dry powder vaccines utilizing thin film freezing technology.
- In March 2022, Cure Pharmaceutical, Milagro Pharmaceuticals, and Milagro Pharmaceuticals collaborated to register and sell Cure's oral thin film drugs in Mexico.
Thin Film Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Target Disorders
4.2.2 Increasing Investments for Pharmaceutical Developments
4.3 Market Restraints
4.3.1 Availability of Substitute Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product Type
5.1.1 Oral Thin Film
5.1.2 Transdermal Thin Film
5.2 By Indication
5.2.1 Schizophrenia
5.2.2 Migraine
5.2.3 Opioid Dependence
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ZIM Laboratories Limited
6.1.2 Aquestive Therapeutics
6.1.3 Indivior PLC
6.1.4 Tesa SE (Tesa Labtec GmbH)
6.1.5 Pfizer, Inc.
6.1.6 ARx, LLC.
6.1.7 Solvay
6.1.8 Intelgenx Corp
6.1.9 AdexPharma
6.1.10 Sumitomo Dainippon Pharma Co. Ltd
6.1.11 Novartis AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Thin Film Drugs Industry Segmentation
As per the report's scope, thin film drugs have surfaced as an alternative to tablets or capsules due to their efficient therapeutic results. The drugs are made of polymers that quickly dissolve when kept in the mouth or buccal cavity, supplying the drug directly to the systemic circulation in the body. The Thin Film Drugs Market is segmented by Product Type (Oral Thin Film, Transdermal Thin Film), By Indication (Schizophrenia, Migraine, Opioid Dependence, and Others), and by geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The by eport also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Product Type | |
| Oral Thin Film | |
| Transdermal Thin Film |
| By Indication | |
| Schizophrenia | |
| Migraine | |
| Opioid Dependence | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Thin Film Drugs Market Research FAQs
What is the current Global Thin Film Drugs Market size?
The Global Thin Film Drugs Market is projected to register a CAGR of 9.30% during the forecast period (2024-2029)
Who are the key players in Global Thin Film Drugs Market?
ZIM Laboratories Limited, Aquestive Therapeutics, Indivior PLC, Tesa Labtec GmbH and Pfizer, Inc. are the major companies operating in the Global Thin Film Drugs Market.
Which is the fastest growing region in Global Thin Film Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Thin Film Drugs Market?
In 2024, the North America accounts for the largest market share in Global Thin Film Drugs Market.
What years does this Global Thin Film Drugs Market cover?
The report covers the Global Thin Film Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Thin Film Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Thin Film Drug Industry Report
Statistics for the 2024 Thin Film Drug market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Thin Film Drug analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
